NASDAQ: STTKShattuck Labs Inc Stock
$1.03-0.02 (-1.9%)
Updated May 20, 2025
STTK Price
$1.03
Fair Value Price
N/A
Market Cap
$49.34M
52 Week Low
$0.69
52 Week High
$7.83
P/E
-0.74x
P/B
0.73x
P/S
10.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.61M
Earnings
-$70.61M
Gross Margin
100%
Operating Margin
-1,532.96%
Profit Margin
-1,533%
Debt to Equity
0.14
Operating Cash Flow
-$56M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
STTK Overview
Shattuck Labs Incorporated is a clinical-stage biotechnology company developing bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune diseases. The company's lead program, SL-172154, designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is undergoing a Phase 1 trial. A second compound, SL-279252, is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Shattuck Labs was incorporated in 2016 and is headquartered in Austin, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STTK's potential to beat the market
- STTK doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
STTK
RankedUnranked of 454
RankedUnranked of 454
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $47.20 | A | |
| $8.30 | A | |
| $65.30 | A |
Be the first to know about important STTK news, forecast changes, insider trades & much more!
STTK News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STTK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STTK is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STTK is good value based on its book value relative to its share price (0.73x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
STTK is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more STTK due diligence checks available for Premium users.
Valuation
STTK fair value
Fair Value of STTK stock based on Discounted Cash Flow (DCF)
Price
$1.03
Fair Value
$1.44
Undervalued by
28.39%
STTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
STTK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.74x
Industry
-156.07x
Market
25.56x
STTK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.73x
Industry
4.37x
STTK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STTK's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.7M
Profit Margin
0%
STTK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
STTK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$77.2M
Liabilities
$9.6M
Debt to equity
0.14
STTK's short-term assets ($66.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STTK's short-term assets ($66.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STTK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.0M
Investing
$15.6M
Financing
-$57.0k
STTK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STTK vs Biotech Stocks
Shattuck Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.